Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp provide an overview of age-related macular degeneration and risk of developing geographic atrophy (GA).

Jayanth Sridhar, MD, Nancy M. Holekamp, MD, FASRS, and David R. Lally, MD, share their thoughts on measuring visual changes to determine how their patients’ geographic atrophy is progressing.

An expert panel reviews the burden of geographic atrophy, and the various tools patients can use to help manage that burden.

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp discuss numerous ways geographic atrophy can impact the caregiver’s quality of life.

A panel of experts shares their thoughts on communicating with patients with mild, intermediate and neovascular age-related macular degeneration about treatment, compliance, and the potential to develop geographic atrophy.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss progression of geographic atrophy and what should be discussed with patients.

David R. Lally, MD, and Jayanth Sridhar, MD, comment on the use of imaging tools to for diagnosis and measuring progression of geographic atrophy.

Jaynath R. Sridhar, MD, shares insights into managing geographic atrophy in his clinic given that there is no FDA-approved treatment.

An expert panel provides an overview of pathophysiological changes in geographic atrophy, ongoing research and promising new treatment options.

A panel of experts discuss clinical data with pegcetacoplan for treatment of geographic atrophy.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss pegcetacoplan dose frequency in treating geographic atrophy.

Eleonora M. Lad, MD, PhD, shares her approach to treating subfoveal lesions and geographic atrophy in both eyes.

A panel of experts comments on the safety data of pegcetacoplan in geographic atrophy and their approach to monitoring patients.

Drs Eleonora M. Lad and Nancy M. Holekamp review other emerging treatment options for geographic atrophy.

An expert panel discusses the role of complement C3 vs C5 therapies and provides guidance for treatment selection in geographic atrophy.

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp share insights to ensure adherence to therapy once started.

A panel of experts discuss what clinics need to consider when introducing new geographic atrophy treatments in their practice.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss the need to improve the referral process through educating physicians about geographic atrophy.

Eleonora M. Lad, MD, PhD, shares how advances in ocular imaging, including AI tools, can improve diagnosis of geographic atrophy going forward.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp share takeaways for health care professionals taking care of patients with geographic atrophy and earlier stages of age-related macular degeneration.